Microcap Ledger Acurx Pharmaceuticals, Inc. $ACXP
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Staten Island, NY
- Fiscal year end
- December 31
- Shares outstanding
- 5,269,921 [10-Q 2026-08-13]
What the company doesAI summary of filing
Acurx Pharmaceuticals is a late-stage biopharmaceutical company developing antibiotics that target Gram-positive bacteria by inhibiting the DNA polymerase IIIC enzyme. The company's lead product candidate, ibezapolstat, has completed Phase 2 clinical trials for treating Clostridioides difficile infection and is advancing toward Phase 3 trials; the company is pre-revenue and exploring partnerships for late-stage development and commercialization. Acurx's pipeline includes early-stage candidates targeting methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae, among other resistant Gram-positive pathogens. [10-K 2026-03-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$3.94M | −$3.12M | $10.66M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | — | −$7.97M | −$6.79M | $7.56M | [10-K 2026-03-12] |
| FY ended Dec 2024 | — | −$14.10M | −$10.38M | $3.71M | [10-K 2026-03-12] |
- Quarterly cash burn
- −$1.56M
- Cash runway Estimate
- ~20.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-12 | 16,892,548 | [10-Q 2024-11-12] |
| 2025-03-17 | 22,042,511 | [10-K 2025-03-17] |
| 2025-05-12 | 23,481,606 | [10-Q 2025-05-12] |
| 2025-08-11 | 1,584,775 | [10-Q 2025-08-11] |
| 2025-11-11 | 2,085,363 | [10-Q 2025-11-12] |
| 2026-03-12 | 2,855,025 | [10-K 2026-03-12] |
| 2026-05-11 | 4,297,738 | [10-Q 2026-05-11] |
| 2026-08-13 | 5,269,921 | [10-Q 2026-08-13] |
- Shelf registration
- S-1 filed 2026-09-08; declared effective 2026-09-17 [S-1 2026-09-08]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-03-28. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-03-28 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-03-28] |
| 2025-02-26 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-02-26] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-17 | 424B3 | Prospectus or prospectus supplement |
| 2026-09-08 | S-1 | Registration statement |
| 2026-09-01 | DEF 14A | Proxy statement |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-05-12 | 424B3 | Prospectus or prospectus supplement |
| 2026-05-12 | 424B3 | Prospectus or prospectus supplement |
| 2026-05-11 | 10-Q | Quarterly report |
| 2026-05-04 | S-1 | Registration statement |
| 2026-05-04 | S-1 | Registration statement |
| 2026-04-16 | 8-K | Material agreement entered; Unregistered sale of equity; Other events |
| 2026-04-16 | 424B5 | Prospectus or prospectus supplement |
| 2026-03-12 | 10-K | Annual report |
Alerts for $ACXP
Email me when Acurx Pharmaceuticals, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.